SOURCE: Medistem Laboratories

February 20, 2008 14:01 ET

Medistem Licensee Seeks to Relocate and Expand Stem Cell Banking

Institute of Cellular Medicine Closes Costa Rican Banking Operations

SCOTTSDALE, AZ--(Marketwire - February 20, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) was notified today by its licensee, the Institute for Cellular Medicine (ICM), that it closed its umbilical cord bank in Costa Rica due to costly and onerous business and regulatory requirements.

ICM stated that they are seeking to create a full service adult stem research laboratory and bank in a more favorable business jurisdiction. The new bank will include a fully integrated facility having the ability to isolate, process and store adult stem cells from sources such as bone marrow, teeth, fat, menstrual blood, and cord blood.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information